Core Insights - Inventiva announced the publication of a clinical study in the Journal of Hepatology, demonstrating the efficacy of lanifibranor in treating metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes (T2D) [1][2][3] Clinical Study Results - The proof-of-concept trial involved 38 patients with MASLD and T2D, showing a 44% reduction in intrahepatic triglycerides (IHTG) after 24 weeks of treatment with lanifibranor, compared to a 12% reduction in the placebo group [2][6] - A higher proportion of patients treated with lanifibranor achieved over 30% liver triglyceride reduction (65% vs. 22%) and MASLD resolution (25% vs. 0%) [2][6] - Secondary endpoints indicated improvements in glycemic control, lipid profiles, hepatic insulin sensitivity, muscle glucose disposal, and adipose tissue function, with no safety concerns reported [2][6] Mechanism of Action - Lanifibranor is a pan-PPAR agonist that activates all three PPAR isoforms, contributing to antifibrotic, anti-inflammatory, and beneficial metabolic changes [8] - The balanced activation of PPARα, PPARδ, and partial activation of PPARγ is believed to enhance the drug's tolerability profile [8] Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH and other diseases with significant unmet medical needs [9] - The company is advancing lanifibranor through a pivotal Phase III clinical trial (NATiV3) for MASH treatment [10] - Inventiva has suspended clinical efforts related to odiparcil to concentrate on lanifibranor's development [11]
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology